Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer

An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer

To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer

Inclusion Criteria:

• Histologically-confirmed intestinal GC (T2-T4)
• Local or locally advanced stage II or stage III gastric cancer of an upper part of the stomach or GE junction
• Lymph node positive or negative
• Metastasis negative
• Resection with curative intent (R0, D2)
• Chemo- and radiotherapy naïve
• Measurable lesion according RECIST
• Written informed consent

Exclusion Criteria:

• Aged below 45 or over 70
• Prior gastric surgery
• Active ILD